"This particular study comes from our human randomized trial that we hope will be the final step before FDA approval for the technology,” says Mathew D. Sorensen, MD, MS, FACS.
In this video, Mathew D. Sorensen, MD, MS, FACS, discusses the background and learning curve of ultrasonic propulsion stone treatment, from the study, “Randomized control trial of ultrasonic propulsion to facilitate clearance of chronic residual fragments,” presented recently at the 2021 American Urological Association Annual Meeting. Sorensen is an associate professor and residency program director of the department of urology at the University of Washington, Seattle, Washington.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.